Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
r
eports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Targeted Therapies in Asthma: KOL Insight (2017)
    Learn More Targeted Therapies in Asthma: KOL Insight (2017)
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the...
  • Ulcerative Colitis: KOL Insight 2016
    Learn More Ulcerative Colitis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Protagonist Therapeutics...
  •  Colorectal Cancer: KOL Insight 2016
    Learn More Colorectal Cancer: KOL Insight 2016
    KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel...
  • Type 2 Diabetes Mellitus: KOL Insight (2016)
    Learn More Type 2 Diabetes Mellitus: KOL Insight (2016)
    Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists (AACE),...
  • Multiple Sclerosis: KOL Insight 2016
    Learn More Multiple Sclerosis: KOL Insight 2016
    Latest Update Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the...
  • Prostate Cancer: KOL Insight 2016
    Learn More Prostate Cancer: KOL Insight 2016
    Latest Update Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib]...
  • Rheumatoid Arthritis: Payer Insight 2016
    Learn More Rheumatoid Arthritis: Payer Insight 2016
    Latest Update This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and...
  • Hepatitis C: KOL Insight
    Learn More Hepatitis C: KOL Insight
    As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has shifted to...
  • Malignant Melanoma: KOL Insight 2016
    Learn More Malignant Melanoma: KOL Insight 2016
    New combinations emerging as immunotherapies become the backbone therapy Immunotherapies have become the go-to treatment for malignant melanoma, and with good reason. Not only are they proving to be the most effective...
  • Chronic Lymphocytic Leukaemia: KOL Insight
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight
    Latest Update Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of...
  • Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Learn More Non Small Cell Lung Cancer (NSCLC): KOL Insight
    Latest Update Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination...
  • Multiple Sclerosis: Payer Insight
    Learn More Multiple Sclerosis: Payer Insight
    Latest Update Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive...
  • Psoriasis: KOL Insight
    Learn More Psoriasis: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new data from two...
  • Age-Related Macular Degeneration (AMD): KOL Insight
    Learn More Age-Related Macular Degeneration (AMD): KOL Insight
    Innovation on all fronts as drug-makers and doctors reimagine wAMD treatment Find out how next-generation VEGF inhibitors and other pipeline drugs will transform wet age-related macular degeneration (wAMD) treatment...
  • Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis (IPF): KOL Insight
    What’s on the KOL ‘wish list’ for the next generation of IPF treatments? Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them?...
  • Multiple Myeloma: KOL Insight
    Learn More Multiple Myeloma: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved